To do this, we analyzed first the correlation between CDK12 expression and disease course in a retrospective consecutive cohort of ~2400 breast cancer patients28, with complete clinicopathological follow-up data (median 14.1 years), unstratified or stratified by type of adjuvant systemic therapy. This evidence concerns the gene CDK12 and breast cancer.